Dr. Sam Masket developed an IOL to prevent negative dysphotopsia, the dark or grey arc-shaped shadow seen in the temporal field of vision following uncomplicated cataract surgery.

Hydroxychloroquine (HCQ; Plaquenil, Sanofi-Synthelabo, Inc, Paris, France) is used to treat autoimmune diseases such as systemic lupus erythematous and rheumatoid arthritis. With long-term exposure, HCQ is known to cause a toxic retinopathy with rates varying between 1% to as high as 7.5% in patients.1 Funduscopic findings of HCQ retinal toxicity range from early, fine retinal pigment epithelium stippling of the macula to the characteristic bilateral bull's eye maculopathy.1 Cystoid macular edema (CME) has been rarely and briefly described in the literature as associated with HCQ retinal toxicity with differing interpretations regarding the angiographic features of the CME.

Intracameral injection is an effective method for preventing infection, but no controlled study has been published in the United States.

To compare the newer formulae, the optical coherence tomography (OCT)-based intraocular lens (IOL) power formula (OCT formula) and the Barrett True-K formula (True-K), with the methods on the American Society of Cataract and Refractive Surgery (ASCRS) calculator in eyes with previous myopic LASIK/photorefractive keratectomy (PRK).

To determine whether migraine is associated with an increased risk of developing ocular motor cranial nerve palsies (OMCNP).

To examine the association between glaucoma and motor vehicle collision (MVC) involvement among older drivers, including the role of visual field impairment that may underlie any association found.